Hepatitis E virus (HEV) infection is a cause of hepatitis in humans worldwide. Recently, persistent and chronic HEV infections have been recognized as a serious clinical problem, especially in immunocompromised individuals. To date, there are no FDA-approved HEVspecific antiviral drugs. In this study, we designed and evaluated antisense peptide-conjugated morpholino oligomers (PPMO) as potential HEV-specific antiviral compounds. Two geneticallydistinct strains of human HEV, genotype 1 Sar55 and genotype 3 Kernow C1, which cause acute and chronic hepatitis, respectively, were used to evaluate PPMO inhibition of viral replication in liver cells. Four anti-HEV PPMOs tested led to a significant reduction in the levels of viral RNA and HEV capsid protein as well as luciferase yield from Sar55 replicons in S10-3 liver cells, indicating an effective inhibition of HEV replication. PPMO HP1, which targets the ORF1 translation initiation region, was also effective against the genotype 3 Kernow C1 strain in stably-infected HepG2/C3A liver cells. The antiviral activity observed was specific, doseresponsive, potent and effective, suggesting that further exploration of HP1 as a potential HEVspecific antiviral agent is warranted.
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INTRODUCTION

Hepatitis E virus (HEV) is a single-stranded positive-sense RNA virus in the family
Hepeviridae (Emerson et al., 2004) . HEV is an etiologic agent of acute hepatitis in humans, and is endemic to various tropical and subtropical regions of the world, where it causes both sporadic cases and epidemic outbreaks. Sporadic HEV infections with disease consequences also occur in non-endemic regions (Kamar et al., 2014; Khuroo, 2011) . In pregnant women, HEV infection can lead to fulminant hepatitis that has a mortality rate of up to 30% (Jameel, 1999; Kumar et al., 2013) . The World Health Organization (WHO) estimates that there are over 3 million acute cases of hepatitis E and over 56,600 deaths annually (WHO, 2014) . Hepatitis E is now a recognized zoonotic disease, and strains of HEV from pig, chicken, mongoose, rabbit, rat, ferret, bat, fish and deer have been genetically characterized (Haqshenas et al., 2001; Li et al., 2005; Meng, 2011; Meng et al., 1997) . More recently, chronic and persistent HEV infections have been reported in increasing numbers of immunocompromised individuals in industrialized countries, including organ transplant recipients and leukemia, lymphoma and HIV/AIDS patients (Kamar et al., 2014) . Chronic hepatitis E has now become a significant clinical problem, warranting an effective antiviral drug, especially for management of HEV infection in immunosuppressed individuals (Kamar et al., 2014) .
The HEV genome is approximately 7.2 kb in length and consists of three open reading frames (ORFs) (Tam et al., 1991) . ORF1 encodes a polyprotein which is supposed to be cleaved to produce all the putative nonstructural proteins involved in HEV replication. ORF2 encodes the capsid protein, the major structural protein in the HEV virion. ORF3 encodes a multi-functional phosphoprotein that is essential for establishing HEV infection in macaques and pigs (Graff et al. , 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   4 which start from two closely spaced initiation codons in different reading frames (Graff et al., 2006) .
HEV strains are highly diverse in sequence and those strains infecting humans are classified into four major genotypes (genotypes 1-4) (Lu et al., 2006) . All four genotypes of human HEV belong to the genus Orthohepevirus. HEV genotypes 1 and 2 are restricted to humans with no known animal reservoir, whereas genotypes 3 and 4 are known to be zoonotic, and infect several animal species in addition to humans (Ahmad et al., 2011; Meng, 2010) . The identification of new HEV strains has prompted a recent proposal from the HEV Study Group of ICTV to reorganize the family Hepeviridae in order to accommodate a more elaborate taxonomy (Smith et al., 2014) .
There is no specific anti-HEV drugs though it has been over two decades since the sequence of the first full-length HEV genome was published (Tam et al., 1991) . Off-label use of ribavirin and pegylated interferon for treatment of acute and chronic hepatitis E patients has been reported (Gerolami et al., 2011; Kamar et al., 2010; Mallet et al., 2010; Wedemeyer et al., 2012) , but there are safety and efficacy concerns with respect to those options. Ribavirin belongs to the FDA Pregnancy Risk Category X and is not recommended for use by pregnant women. Thus, there is a pressing need for the development of a specific anti-HEV therapeutic, especially for treating immunocompromised patients and for chronic infections.
Phosphorodiamidate morpholino oligomers (PMO) are nuclease-resistant single-stranded DNA analogs containing a backbone of morpholine rings and phosphorodiamidate linkages (Summerton, 1999) . PMO bind to mRNA by Watson-Crick base pairing and can interfere with translation through steric blockade of the AUG-translation start site region. Conjugation of PMO to an arginine-rich cell penetrating peptide, yielding peptide-conjugated PMO (PPMO), facilitate   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 5 delivery into cells (Abes et al., 2006; Summerton, 1999 (Stein, 2008) , the PPMOs for this study were designed to target genomic sequence of HEV Sar55 strain. PPMO HP1 and HP2 are complementary to the 5'end of genomic and subgenomic RNA, respectively ( Fig. 1 and Table 1 ). HP3U is complementary to sequence in the terminal region of the 3' UTR. HPN3 is reverse complement to HP1 and was intended to interfere with the synthesis of genomic RNA. A nonsense-sequence PPMO CP1 (Zhang et al., 2007) , having little agreement with HEV or human mRNA sequences, was used as a negative control PPMO. CP1
with fluorescein conjugated at its 3'end (CP1-Fl) was used in the PPMO uptake assay. PPMOs were synthesized with an arginine-rich cell-penetrating peptide (P7) conjugated at the 5'end at AVI BioPharma Inc (Corvallis, OR) as previously described (Abes et al., 2006) .
2.2.
Cell-free translation. PPMO target sequences were cloned upstream of the luciferase gene in reporter vector pCiNeoLucr as previously described (Zhang et al., 2007) . Briefly, oligomers of 30-nt in length containing the target sequence for PPMO HP1, HP2, and HP3U were each cloned upstream of luciferase coding sequence in pCiNeoLucr vector. The in vitro transcription and translation were done as previously described (Zhang et al., 2008 The PPMO uptake assay was performed in uninfected S10-3 cells. PPMO CP1-Fl was added to the medium at a final concentration of 8 M and incubated at 37C for 4 h. The medium was removed and the cells were rinsed with PBS pH7.2. Fluorescence microscopy was conducted to assess PPMO uptake efficiency.
Transfection of S10-3 cells with HEV RNA in vitro transcribed from pSK-E2 (an infectious cDNA clone of HEV Sar55 strain) or pSK-E2-Luc (containing luciferase reporter) was performed as previously described (Nan et al., 2014a; Nan et al., 2014b) . For PPMO treatment of the S10-3 cells, cell culture supernatant was discarded 5 hours after RNA transfection and the cells then rinsed twice with Opti-MEM. PPMOs suspended in 0.5 mL Opti-MEM were then added to the cell monolayer. Four hours after PPMO treatment, 1 mL DMEM with 10% FBS was added to each well. The cells were then cultured at 34.5ᵒC for 7 days prior to further analysis for viral protein or RNA. Luciferase activity from pSK-E2-Luc in the cells was determined by using the Bright-Glo™ Luciferase Assay System (Promega, Madison, WI).
The HEV genotype 3 Kernow C1 strain p6 was used to infect HepG2/C3A cells at a multiplicity of infection (MOI) of 1 (Shukla et al., 2011) . IFA with chimpanzee anti-HEV antibody was conducted to confirm the virus replication. Subsequently, the Kernow-infected cells were seeded into 12-well plates. PPMO was then added to the HepG2/C3A cells in fresh medium once every two days for 6 days (3 treatments total). The cells were maintained at 37ᵒC
and harvested for protein and RNA analysis one day after the final PPMO treatment.
Cell viability assay. Viability of S10-3 cells after PPMO treatment was determined with
CellTiter-Glo® Luminescent Cell Viability Assay (Promega). Briefly, S10-3 cells were treated with the PPMO as described above and lysed 48 h later with 1X reporter lysis buffer. CellTiter- Glo Reagent was mixed with the lysate at 1:1 ratio in a 96-well plate and luminescence signal was measured.
Immunofluorescence assay (IFA).
IFA and confocal fluorescence microscopy were carried out as reported previously with chimpanzee antibody against the HEV capsid protein (Nan et al., 2014b).
Western blot analysis.
Cells were lysed in Laemmli sample buffer. Total protein was subjected to sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blotting as described previously (Patel et al., 2010; Zhang et al., 2007 ). An anti-HEV ORF2 monoclonal antibody (EMD Millipore, Billerica, MA) was used at dilution of 1:1000. The Quantity One Program (Version 4.6) and a ChemiDoc XRS imaging system (Bio-Rad Laboratories, Hercules, CA) were used for digital signal acquisition and densitometry analyses.
-tubulin was also detected as a protein load control.
Reverse transcription and real-time PCR (RT-qPCR). RNA isolation, reverse
transcription and real-time PCR were performed as previously described (Nan et al., 2012; Nan et al., 2014c) . For the detection of HEV-specific RNA, HEV specific reverse primer (Sar55-R3, CAGAATCCACGCAGACCTTA) was used in reverse transcription. Primers Sar55-F3
(TGAGTTTGATTCCACCCAGA) and Sar55-R3 were used for real-time PCR on Sar55 cDNA.
For absolute quantification of HEV RNA, the pSK-E2 (Sar55) plasmid served as the template to establish standard curve.
2.8. Statistical analysis. The significant differences of luciferase level or HEV RNA copies between the groups of cells in the presence or absence of PPMO were assessed by Student t-tests.
A two tailed P-value of less than 0.05 was considered significant. HEV-targeted PPMO reduced luciferase signal significantly (Fig. 2) . PPMO HP1 produced a 99% reduction at 100 nM (Fig. 2) . Similarly, PPMO HP2, and HP3U reduced luciferase expression by around 90% at 200 nM (Fig. 2 ). All PPMOs behaved in a dose-dependent manner with HP1
producing the most potent inhibition.
PPMOs inhibit HEV replication in S10-3 liver cells.
We next conducted a PPMO uptake assay in uninfected S10-3 cells with PPMO CP1-Fl. Highly efficient uptake of the CP1-Fl was observed, as indicated by the presence of green fluorescence signal present in all cells (Fig. 3A) .
Having established that PPMO enter S10-3 cells effectively, we next tested whether the anti-HEV PPMO were able to inhibit HEV replication. S10-3 cells were transfected with full-length Sar55 RNA, then treated with 16 μM PPMO. PPMO HP1, HP2, HP3U and HPN3 produced marked reduction of capsid protein expression, indicating inhibition of HEV replication, while CP1 had minimal effect (Fig. 3B) . The results indicate that the four HEV-targeted PPMOs generated specific inhibition of HEV replication.
We also tested whether the PPMO produced cytotoxicity to S10-3 cells, as an impact on cell viability could produce non-specific inhibition of viral replication. When the cells were   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 treated with 16 μM PPMO HP1 under the same conditions as the antiviral assays above, no impact on cell viability was observed by the cell viability assay (data not shown). Luciferase yields in cells treated with the 16 μM PPMO were significantly lower than that in mock-treated cells (Fig. 4A ).
PPMO treatment generates dose
Further evaluations showed that PPMO HP1, HPN3 and HP3U generated dose-dependent reductions of luciferase expression (Fig. 4B ). Luciferase expression in the cells treated with HP1
at 2, 4, and 8 μM was reduced by 53%, 94%, and 99%, respectively, compared to that of mocktreated control. PPMO HPN3 reduced luciferase expression by 40%, 90% and 99%, when used at 2, 4, and 8 μM respectively. PPMO HP3U at 2, 4, and 8 μM reduced the luciferase expression by 78%, 86% and 92%, respectively.
Of the three PPMOs tested above in two cell-based systems, HP1 produced the most potent inhibition of HEV replication. To further evaluate HP1 in S10-3 cells, we measured 
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We next tested if PPMO treatment reduced the level of HEV RNA production. Cells were transfected with Sar55 RNA and treated with 8 μM HP1. HEV RNA present in the supernatant of cell cultures was detected by RT-qPCR at seven days post transfection. The HP1 treatment led to reduction of HEV RNA from 2.8 x 10 6 copies to less than 3.1 x 10 4 copies per mL (Fig. 4D) .
The results were consistent with those of capsid protein detection and the luciferase reporter assay (pSK-E2-Luc) described above. (Fig. 5C ). Evaluation of capsid protein expression showed that HP1 inhibition of Kernow C1 replication was dose-dependent (Fig. 5D ).
PPMO HP1 inhibits HEV
Taken together, the data from experiments using two HEV genotypes and three different cell-based systems showed PPMO HP1 to be an effective inhibitor of HEV replication. 
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